SCHEMBL5369080

SCHEMBL5369080

CC(C)(C)OC(=O)N1CCN(c2cccc3ncccc23)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.54
GBA1 P04062 2/20 0.53
DTYMK P23919 1/20 0.52
GPR119 Q8TDV5 4/20 0.50
TRPV1 Q8NER1 1/20 0.50
ACHE P22303 2/20 0.49
CKS1B P61024 1/20 0.47
SKP1 P63208 1/20 0.47
SKP2 Q13309 1/20 0.47
PDGFRB P09619 1/20 0.47
IDE P14735 2/20 0.47
KIT P10721 2/20 0.46
MAP4K4 O95819 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
SMARCA2 P51531 1/20 0.45
SMARCA4 P51532 1/20 0.45
PBRM1 Q86U86 1/20 0.45
CHRM2 P08172 1/20 0.45
CHRM4 P08173 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2422976 0.91 PDGFRB (0.55) POLBGBA1DTYMKGPR119ACHE
SCHEMBL5363583 0.84 MAP4K4 (0.52) POLBGBA1GPR119ACHECKS1B
SCHEMBL22391780 0.82 POLB (0.58) POLBGBA1DTYMKGPR119ACHE
SCHEMBL10317314 0.82 POLB (0.58) POLBGBA1DTYMKGPR119ACHE
SCHEMBL430227 0.82 CYP2C9 (0.52) GBA1GPR119CKS1BSKP1SKP2
SCHEMBL1048457 0.81 POLB (0.55) POLBGBA1DTYMKGPR119TRPV1
SCHEMBL19000121 0.81 DTYMK (0.41) POLBGBA1DTYMKGPR119TRPV1
SCHEMBL21401570 0.81 POLB (0.57) POLBGBA1DTYMKGPR119TRPV1
SCHEMBL14206364 0.81 POLB (0.57) POLBGBA1DTYMKGPR119ACHE
SCHEMBL30592004 0.81 POLB (0.57) POLBGBA1DTYMKGPR119ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112390751-B Toll-like receptor-7 small molecule inhibitor and preparation method thereof 清华大学 2022-07-05 CN disclosed
CN-112390751-A Toll-like receptor-7 small molecule inhibitor and preparation method thereof 清华大学 2021-02-23 CN disclosed
US-7160888-B2 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT COMPANY LLC (US) 2007-01-09 US disclosed
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
EP-1660497-A1 [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2006-05-31 EP disclosed
WO-2005019215-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2005-03-03 WO disclosed
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia DRD1, DRD2, DRD3 POLB 2792/4885GBA1 237/4885DTYMK 3277/4885
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 POLB 2792/4885GBA1 237/4885DTYMK 3277/4885
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 POLB 2792/4885GBA1 237/4885DTYMK 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.